First-line pembrolizumab in metastatic non-small cell lung cancer: A clinical text-mining analysis of effectiveness, costs, and trial eligibility

International Journal of Lung Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles